{
    "nct_id": "NCT04411641",
    "official_title": "A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis",
    "inclusion_criteria": "Inclusion criteria :\n\n* 18 to 60 years of age inclusive\n* Diagnosis of nonrelapsing secondary progressive multiple sclerosis according to the 2017 McDonald criteria\n* Expanded disability status scale (EDSS) between 3.0 to 6.5 points inclusive, at screening\n* The participant must have documented evidence of disability progression observed during the 12 months before screening\n* Absence of clinical relapses for at least 24 months\n* Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\n* Is not a WOCBP OR\n* Is a WOCBP and agrees to use an acceptable contraceptive method\n\nExclusion criteria:\n\n* The participant has conditions that would adversely affect study participation such as short life expectancy.\n* History of organ transplant.\n* Evidence of infection with human immuodeficiency virus (HIV), transplantation, progressive multifocal leukoencephalopathy (PML), active hepatitis B or C, active or latent tuberculosis or other active infections that would adversely affect study participation.\n* Persistent chronic or active or recurring system infection, that may adversely affect participation or IMP administration in this study, as judged by the Investigator.\n* History of malignancy within 5 years prior to screening.\n* History of alcohol or drug abuse within 1 year prior to screening.\n* Hospitalized for psychiatric disease within 2 years prior to screening.\n* Clinically significant laboratory abnormalities (including evidence of liver injury) or electrocardiogram abnormalities at screening\n* Bleeding disorder, known platelet dysfunctionat any time prior to the screening visit\n* A platelet count <150 000/Î¼L at the screening visit\n* A history of significant bleeding event within 6 months prior to screening, according to the Investigator's judgment such as, but not limited to cerebral or gastrointestinal bleeding.\n* Lymphocyte count below the lower limit of normal at screening.\n* Recent live (attenuated) vaccine within 2 months before the first treatment visit.\n* Recent major surgery (within 4 weeks of screening) or planned major surgery during the study.\n* The participant has received medications/treatments for MS within a specified time frame.\n* Receiving potent and moderate inducers or inhibitors of cytochrome P450 3A (CYP3A) or potent inhibitors of CYP2C8 hepatic enzymes.\n* Receiving anticoagulant or antiplatelet therapy (such as aspirin>81mg/day, clopidogrel, warfarin).\n* Contraindications to magnetic resonance imaging (MRI).\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 60 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}